Biotech startups in Boston, Massachusetts
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Ratio Therapeutics | Boston | Series C | $70.0M | 2026-07-31 |
| Neurable | Boston | Series A | $35.0M | 2025-12-19 |
| VideaHealth | Boston | Series B | $40.0M | 2025-01-28 |
| Ascidian Therapeutics | Boston | Series A | $40.0M | 2023-11-08 |
| Asimov | Boston | Series B | $175.0M | 2023-01-05 |
| Emulate | Boston | Series F | $47.1M | 2024-03-20 |
| Precede Biosciences | Boston | Series B | $63.5M | 2026-01-12 |
| Superluminal Medicines | Boston | Series B | $65.5M | 2026-09-03 |
8 rows of the CSV in 5 of its 18 columns.
- The 211 biotech startups in Boston, Massachusetts have raised $11.7B in total.
- 42 of them closed their most recent round in the last 12 months, $1.5B combined.
- The largest of those rounds is Solstice Oncology's $225.0M Series A, dated September 2026.
- The most recent is Delix Therapeutics' $100.0M Series C on 9 November 2026.
- MassChallenge is an investor in 5 of them, more than any other fund.
- Health care is the most common other sector, with 175 companies (83%).
- 44% were founded in 2020 or later; the median founding year is 2019.
- The most common team size is 11 to 50 employees (46% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
22 of 211| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Series C | $100.0M | 2026-11-09 | $244.1M | Gaingels, RA Capital Management, Dolby Family Ventures +2 | 11 to 50 | 2019 |
| INIA Biosciences | INIA Biosciences develops non-invasive, home-administered medical devices to manage chronic inflammatory diseases. | Biotech | Seed | $1.5M | 2026-09-08 | $1.5M | MassChallenge, MedTech Innovator | 1 to 10 | 2020 |
| Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| Dash Bio | Dash Bio develops automated laboratory workflows and software to support drug development through bioanalysis services. | Artificial intelligence | Series A | $30.0M | 2026-08-03 | $47.5M | Freestyle Capital, Swift Ventures, LifeX Ventures +1 | 11 to 50 | 2024 |
| Ratio Therapeutics | Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. | Biotech | Series C | $70.0M | 2026-07-31 | $160.0M | Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments | 11 to 50 | 2021 |
| Cerevance | Cerevance develops novel therapeutics for neurological diseases. | Biotech | Series C | $20.0M | 2026-05-12 | $209.5M | Google Ventures, Casdin Capital, Foresite Capital +1 | 51 to 100 | 2016 |
| Third Arc Bio | Third Arc Bio develops multifunctional antibodies for inflammatory and immunology diseases. | Biotech | Series A | $52.0M | 2026-02-04 | $217.0M | T. Rowe Price, Cormorant Asset Management, Foresite Capital +1 | 11 to 50 | 2022 |
| Precede Biosciences | Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. | Biotech | Series B | $63.5M | 2026-01-12 | $140.5M | Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 | 11 to 50 | 2005 |
| Neurable | Neurable develops AI tools for translating brain signals and brain-computer interface technology. | Artificial intelligence | Series A | $35.0M | 2025-12-19 | $57.3M | National Science Foundation, Global Brain Corporation, Metaplanet +1 | 11 to 50 | 2015 |
| Biometry | Biometry develops diagnostic tools for patients with chronic respiratory conditions. | Artificial intelligence | Seed | $2.2M | 2025-12-19 | $7.8M | MassChallenge, Elevate Ventures, Sidecar Angels +1 | 11 to 50 | 2013 |
| AI Proteins | AI Proteins designs and engineers miniprotein therapeutics using artificial intelligence. | Artificial intelligence | Series A | $42.5M | 2025-11-19 | $80.4M | Intel Ignite, Lightchain Capital, Cobro Ventures | 11 to 50 | 2021 |
| Elucid | Elucid applies AI to medical images to support precision medicine for cardiovascular disease. | Biotech | Series D | $36.5M | 2025-10-22 | $166.2M | National Science Foundation, Sand Hill Angels, IAG Capital Partners +1 | 101 to 250 | 2013 |
| Folia Health | Folia Health is a platform that securely captures and shares users' health and symptom data. | Biotech | Series A | $10.5M | 2025-10-01 | $17.4M | MassChallenge, Social Starts, Bantam Group +2 | 11 to 50 | 2016 |
| VideaHealth | VideaHealth offers dentistAI software that automatically detects pathologies in dental imaging to help dentists avoid missed diagnoses. | Biotech | Series B | $40.0M | 2025-01-28 | $66.5M | Spark Capital, Zetta Venture Partners, Pillar VC +2 | 51 to 100 | 2018 |
| Cardurion Pharmaceuticals | Cardurion Pharmaceuticals develops cardiovascular therapeutics for heart failure and related diseases. | Biotech | Series B | $260.0M | 2024-07-16 | $603.1M | New Enterprise Associates, Google Ventures, Fidelity +1 | 11 to 50 | 2017 |
| Adaptilens | Adaptilens develops an accommodating intraocular lens for cataract patients. | Biotech | Series A | $17.5M | 2024-04-29 | $19.1M | MassChallenge, Pillar VC, Perceptive Advisors +2 | 1 to 10 | 2019 |
| Emulate | Emulate creates advanced in vitro models to study how diseases, medicines, and chemicals affect human health. | Biotech | Series F | $47.1M | 2024-03-20 | $271.3M | Alumni Ventures, Qiming Venture Partners, National Institutes of Health | 51 to 100 | 2013 |
| Alys Pharmaceuticals | Alys Pharmaceuticals develops immuno-dermatology treatments as a biopharmaceutical company. | Biotech | Seed | $100.0M | 2024-02-12 | $100.0M | Medicxi | 11 to 50 | 2024 |
| Ascidian Therapeutics | Ascidian Therapeutics is a biotechnology company focused on medical and clinical gene therapy. | Biotech | Series A | $40.0M | 2023-11-08 | $90.0M | Apple Tree Partners | 11 to 50 | 2020 |
| Asimov | Asimov uses artificial intelligence to build tools for designing and manufacturing therapeutics. | Artificial intelligence | Series B | $175.0M | 2023-01-05 | $205.0M | Andreessen Horowitz, DCVC, Fidelity +2 | 101 to 250 | 2017 |
| Biofourmis Unicorn | Biofourmis develops healthcare technology platforms that monitor patients at home. | Artificial intelligence | Series D | $20.0M | 2022-07-27 | $463.6M | Sequoia Capital, Intel Capital, Peak XV Partners +1 | 251 to 500 | 2015 |
| Orbita | Orbita sells voice-first and conversational AI software that helps patients engage with digital healthcare. | Artificial intelligence | Series A | $9.0M | 2020-05-27 | $16.5M | MassChallenge, nvp capital, Cultivation Capital +2 | 11 to 50 | 2015 |
Table 1. Biotech startups in Boston, Massachusetts: the 22 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 211.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Delix Therapeutics | Delix Therapeutics develops psychoplastogen therapies that promote neuroplasticity. | Biotech | Series C | $100.0M | 2026-11-09 | $244.1M | Gaingels, RA Capital Management, Dolby Family Ventures +2 | 11 to 50 | 2019 |
| 2 | Ratio Therapeutics | Ratio Therapeutics develops radiopharmaceuticals to treat solid tumors in clinical trials. | Biotech | Series C | $70.0M | 2026-07-31 | $160.0M | Bristol-Myers Squibb, The Pags Group, Schusterman Family Investments | 11 to 50 | 2021 |
| 3 | Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| 4 | Precede Biosciences | Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. | Biotech | Series B | $63.5M | 2026-01-12 | $140.5M | Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 | 11 to 50 | 2005 |
| 5 | Third Arc Bio | Third Arc Bio develops multifunctional antibodies for inflammatory and immunology diseases. | Biotech | Series A | $52.0M | 2026-02-04 | $217.0M | T. Rowe Price, Cormorant Asset Management, Foresite Capital +1 | 11 to 50 | 2022 |
| 6 | AI Proteins | AI Proteins designs and engineers miniprotein therapeutics using artificial intelligence. | Artificial intelligence | Series A | $42.5M | 2025-11-19 | $80.4M | Intel Ignite, Lightchain Capital, Cobro Ventures | 11 to 50 | 2021 |
| 7 | Neurable | Neurable develops AI tools for translating brain signals and brain-computer interface technology. | Artificial intelligence | Series A | $35.0M | 2025-12-19 | $57.3M | National Science Foundation, Global Brain Corporation, Metaplanet +1 | 11 to 50 | 2015 |
| 8 | Dash Bio | Dash Bio develops automated laboratory workflows and software to support drug development through bioanalysis services. | Artificial intelligence | Series A | $30.0M | 2026-08-03 | $47.5M | Freestyle Capital, Swift Ventures, LifeX Ventures +1 | 11 to 50 | 2024 |
| 9 | Cerevance | Cerevance develops novel therapeutics for neurological diseases. | Biotech | Series C | $20.0M | 2026-05-12 | $209.5M | Google Ventures, Casdin Capital, Foresite Capital +1 | 51 to 100 | 2016 |
| 10 | Biometry | Biometry develops diagnostic tools for patients with chronic respiratory conditions. | Artificial intelligence | Seed | $2.2M | 2025-12-19 | $7.8M | MassChallenge, Elevate Ventures, Sidecar Angels +1 | 11 to 50 | 2013 |
Table 2. Biotech startups in Boston, Massachusetts: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | MassChallenge | Startup accelerator | Boston, United States | 5 | 2% | 2 | INIA Biosciences, Biometry |
| 2 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 4 | 2% | 1 | Neurable |
| 3 | Pillar VC | Venture capital firm | Boston, United States | 3 | 1% | ||
| 4 | Fidelity | Investment bank | Boston, United States | 3 | 1% | ||
| 5 | Insight Partners | Private equity firm | New York, United States | 3 | 1% | 1 | Superluminal Medicines |
| 6 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 2 | 1% | 2 | Ratio Therapeutics, Precede Biosciences |
| 7 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 2 | 1% | ||
| 8 | Alumni Ventures | Angel group | Manchester, United States | 2 | 1% | ||
| 9 | Illumina Ventures | Corporate venture arm | Foster City, United States | 2 | 1% | 1 | Precede Biosciences |
| 10 | RA Capital Management | Startup incubator | Boston, United States | 2 | 1% | 2 | Delix Therapeutics, Superluminal Medicines |
| 11 | Foresite Capital | Private equity firm | San Francisco, United States | 2 | 1% | 2 | Cerevance, Third Arc Bio |
| 12 | Sequoia Capital | Venture capital firm | Menlo Park, United States | 2 | 1% | ||
| 13 | LaunchPad Venture | Angel group | Newton, United States | 2 | 1% | ||
| 14 | Joyance Partners | Venture capital firm | San Francisco, United States | 2 | 1% | ||
| 15 | Google Ventures | Corporate venture arm | San Francisco, United States | 2 | 1% | 1 | Cerevance |
Table 3. Biotech startups in Boston, Massachusetts: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 175 | 83% | $10.4B |
| Software | 42 | 20% | $2.3B |
| Artificial intelligence | 27 | 13% | $1.8B |
| Hardware | 12 | 6% | $224.8M |
| Commerce | 2 | 1% | $72.0M |
| Energy | 2 | 1% | $7.8M |
| Education | 1 | 0% | $30.0M |
| Cybersecurity | 1 | 0% | |
| Fintech | 1 | 0% |
Table 4. Biotech startups in Boston, Massachusetts by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in Boston, Massachusetts by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 2 | 5% | $111.5M |
| October 2026 | 3 | 7% | $189.0M |
| September 2026 | 5 | 12% | $317.3M |
| August 2026 | 3 | 7% | $80.0M |
| July 2026 | 2 | 5% | $70.0M |
| June 2026 | 4 | 10% | $52.9M |
| May 2026 | 2 | 5% | $22.0M |
| April 2026 | 4 | 10% | $99.3M |
| March 2026 | 2 | 5% | $3.5M |
| February 2026 | 1 | 2% | $52.0M |
| January 2026 | 7 | 17% | $255.5M |
| December 2025 | 3 | 7% | $57.2M |
| November 2025 | 4 | 10% | $199.7M |
Table 6. Biotech startups in Boston, Massachusetts: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 35 | 17% | $1.3B |
| 2025 | 37 | 18% | $947.1M |
| 2024 | 29 | 14% | $1.4B |
| 2023 | 16 | 8% | $524.6M |
| 2022 | 19 | 9% | $488.4M |
| 2021 | 16 | 8% | $536.2M |
Table 7. Biotech startups in Boston, Massachusetts by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 44 | 21% |
| 2020 to 2022 | 49 | 23% |
| 2015 to 2019 | 70 | 33% |
| 2010 to 2014 | 29 | 14% |
| Before 2010 | 17 | 8% |
Table 8. Biotech startups in Boston, Massachusetts by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 80 | 39% |
| 11 to 50 | 94 | 46% |
| 51 to 100 | 17 | 8% |
| 101 to 250 | 11 | 5% |
| 251 to 500 | 2 | 1% |
| 501 to 1,000 | 1 | 0% |
Table 9. Biotech startups in Boston, Massachusetts by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Boston, Massachusetts. On 16 November 2026 that is 211 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 22 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 211 rows: 46 have no round amount, 0 no city and 25 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Boston, Massachusetts are on the list?
- 211, in the file dated 16 November 2026. 42 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 211 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.